La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference

Rodman & Renshaw Global Investment Conference 2014

SAN DIEGO--()--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City.

Rodman & Renshaw 16th Annual Global Investment Conference Presentation Details

Date: Wednesday, September 10, 2014

Time: 11:40 am Eastern Time

Location: Holmes I Salon @ New York Palace Hotel

Webcast: LJPC Webcast Link

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. LJPC-501, La Jolla’s lead product candidate, is a proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100, La Jolla’s second product candidate, is a first-in-class inhibitor of galectin-3 for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s third product candidate, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis. LJPC-401, La Jolla’s fourth product candidate, is a natural peptide for the potential treatment of iron overload. For more information on La Jolla, please visit http://www.ljpc.com.

Contacts

La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
(858) 207-4264
GTidmarsh@ljpc.com
and
Chester S. Zygmont, III
Senior Director of Finance
(858) 207-4262
czygmont@ljpc.com

Release Summary

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference

Contacts

La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
(858) 207-4264
GTidmarsh@ljpc.com
and
Chester S. Zygmont, III
Senior Director of Finance
(858) 207-4262
czygmont@ljpc.com